Immunotherapy for Autoimmune Diseases: A Double-edged Sword?

Lima Glaucia^*
*Correspondence: Lima Glaucia, Department of Medicine and Epidemiology, Alfaisal University, Riyad 11533, Saudi Arabia, Email:

Introduction

Autoimmune diseases arise when the immune system mistakenly attacks the bodyâ??s own cells, leading to chronic inflammation and tissue damage. Conditions such as rheumatoid arthritis, multiple sclerosis, lupus and type 1 diabetes are among the many autoimmune disorders that significantly impact quality of life. Immunotherapy, which has gained prominence in the treatment of cancer and infectious diseases, is now being explored as a potential solution for autoimmune conditions. However, while immunotherapy holds immense promise, it also comes with inherent risks, making it a double-edged sword [1]. Immunotherapy for autoimmune diseases primarily focuses on modulating the immune system rather than simply suppressing it. Treatments like monoclonal antibodies, immune checkpoint inhibitors and cytokine therapies aim to restore immune balance by targeting specific pathways involved in autoimmunity [2]. Additionally, therapies targeting B cells, such as rituximab, have shown efficacy in multiple sclerosis and lupus.

Description

One of the key advantages of immunotherapy is its potential to provide long-term disease control or even remission. Unlike traditional immunosuppressants, which broadly dampen the immune system and increase susceptibility to infections, newer immunotherapies are designed to act more precisely, reducing unwanted side effects. Some cutting-edge approaches, like CAR-T cell therapy and regulatory T-cell therapies, aim to reprogram the immune system for sustained tolerance, potentially leading to a functional cure for some autoimmune diseases [3,4]. Despite its promise, immunotherapy carries significant risks. By altering immune function, these treatments can sometimes trigger unintended consequences, including an increased risk of infections, secondary autoimmune conditions and even cancer. Immune checkpoint inhibitors, which have revolutionized cancer treatment, can paradoxically induce autoimmune-like reactions in some patients. Similarly, B-cell depletion therapies can lead to impaired immune responses, increasing the risk of severe infections.

Another challenge is patient variability. Not all individuals respond to immunotherapy in the same way and some may experience severe side effects or worsening of their condition. The long-term effects of certain immunotherapies are still being studied and concerns remain about their impact on immune memory and overall health. Additionally, the high cost of these treatments limits accessibility, making widespread adoption difficult [5]. Advancements in precision medicine and biomarker research are expected to refine immunotherapy approaches, making them safer and more effective.

Conclusion

As research progresses, immunotherapy could transform the management of autoimmune diseases, offering hope for long-term remission and improved quality of life. However, the challenge remains in balancing efficacy with safety, ensuring that immune modulation does not lead to unintended harm. Until these concerns are fully addressed, immunotherapy will continue to be both a powerful tool and a potential risk truly a double-edged sword in the fight against autoimmune diseases. Personalized treatment strategies, including genetic profiling and immune system mapping, may help identify the most suitable candidates for specific immunotherapies, minimizing risks. Combination therapies that integrate immunotherapy with conventional treatments are also being explored to enhance efficacy while reducing adverse effects.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Gudowska-Sawczuk, Monika and Barbara Mroczko. “Free light chains as a novel diagnostic biomarker of immune system abnormalities in multiple sclerosis and HIV infection.” Biomed Res Int 2019 (2019).

Google Scholar        Cross Ref    Indexed at

2. El-Menyar, Ayman, Husham Abdelrahman, Ammar Al-Hassani and Mohammad Ellabib, et al. “Clinical presentation and time-based mortality in patients with chest injuries associated with road traffic accidents.” Arch Trauma Res5 (2016):

Google Scholar        Cross Ref     Indexed at

3. Inaba, Kenji, Thomas Lustenberger, Gustavo Recinos and Crysanthos Georgiou, et al. “Does size matter? A prospective analysis of 28–32 versus 36–40 French chest tube size in trauma.” J Trauma Acute Care Surg72 (2012): 422-427.

Google Scholar        Cross Ref     Indexed at

4. López-Otín, Carlos, Maria A. Blasco, Linda Partridge and Manuel Serrano, et al. “Hallmarks of aging: An expanding universe.” Cell186 (2023): 243-278.

Google Scholar        Cross Ref     Indexed at

5. Simell, Birgit, Arja Vuorela, Nina Ekström and Arto Palmu, et al. “Aging reduces the functionality of anti-pneumococcal antibodies and the killing of Streptococcus pneumoniae by neutrophil phagocytosis.” Vaccine29 (2011): 1929-1934.

Google Scholar        Cross Ref     Indexed at